

Pfizer Satellite Symposium at EAHAD 2021

5th February 18:00–19:00 CET (Virtual)

Addressing the known unknowns:

how long-term follow up is evolving our scientific understanding of haemophilia gene therapy

Exploring key scientific considerations from a haematological, hepatological, immunological and psychological perspective.

Agenda:

Co-chairs: Mike Laffan (UK) and Ian Winburn (Pfizer)

Time	Title	Presenter
18:00 CET	Welcome and introduction	Mike Laffan (Co-chair) Professor of Haemostasis and Thrombosis, Department of Haematology at Imperial College, London, UK
18:10 CET	Targeting the liver: insights from a hepatologist	Heiner Wedemeyer Professor and Chairman of the Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany
18:20 CET	Immunological challenges: the missing links	Thierry VandenDriessche Director of the Department of Gene Therapy and Regenerative Medicine, Free University of Brussels (VUB), Belgium
18:30 CET	Psychological impact of gene therapy: the difficult questions	Nicola Dunn Systemic Psychotherapist, Private Practice, and formerly at the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK
18:40 CET	Q&A	All - moderated by the Co-chairs
18:55 CET	Meeting summary and close	Ian Winburn (Pfizer) Vice President, Global Medical Lead, Haemophilia, Endocrine and IEM, UK